Lacosamide
Product Images NDC 14335-330

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 14335-330). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hainan Poly Pharm. Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 3 (Lacosamide 014)

A Kaplan-Meier survival curve showing the proportion of patients over time (up to 170 days) for two groups: Placebo (PBO) and Vimpat. The y-axis represents the proportion of patients, and the x-axis represents time in days. The plot includes risk numbers for each group at various time points and displays statistical values such as p-value, hazard ratio (HR), and 95% confidence interval (CI).*

FDA Label Image

Principal Display Panel (20 mL Vial Carton)

Lacosamide Injection, USP 200 mg/20 mL (10 mg/mL) carton label from Hainan Poly Pharm. Co., Ltd. It is labeled for intravenous use, containing 10 single-dose vials. The packaging includes usage instructions, storage conditions, and barcode, with product identification on all sides.*

FDA Label Image

Image02 (Lacosamideinjection 011)

Chemical structure diagram of Lacosamide, depicting its molecular arrangement with functional groups including an amide, methyl ester, and benzyl moiety.*

FDA Label Image

Image04 (Lacosamideinjection 012)

A bar chart titled 'Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose' comparing seizure reduction percentages for placebo and various doses of VIMPAT across three studies. The chart presents median percent change from baseline seizure frequency with doses of 200 mg/day, 400 mg/day, and 600 mg/day. Statistically significant differences from placebo are indicated with asterisks.*

FDA Label Image

Image05 (Lacosamideinjection 013)

A line graph titled 'Figure 2 – Proportion of Patients by Responder Rate for VIMPAT and Placebo Groups in Studies 2, 3, and 4.' The vertical axis represents responder rate (equal to or greater) ranging from worsening (-100%) to improvement (100%). The horizontal axis shows percent of patients from 0 to 100. Four lines compare placebo and three VIMPAT dosage groups (200 mg/day, 400 mg/day, and 600 mg/day) illustrating the proportion of patients by responder rate in each group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.